Tue, 09th Aug 2016 12:24
** U.S.-listed shares of London-based maker of cannabis-based drugs up about 9 pct at $104.77 premarket ** Company's childhood epilepsy drug, epidiolex, currently in use through an expanded access program, showed marked improvement in median reduction of seizure frequency, data compiled by
Read more(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell on Tuesday in a modest retreat from the previous
Read more(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks fell at the open on Tuesday, slightly reversing the pr
Read more(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock were poised to open lower on Tuesday, indicating a mode
Read more** U.S.-listed shares of the maker of cannabis-based drugs up 4 pct at $91.99 premarket ** The UK-based company has started the second leg of a mid-stage trial testing Epidiolex to treat Dravet syndrome, a rare, treatment-resistant form of childhood epilepsy ** Data from the trial is
Read more